| Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity R Roxburgh, SR Seaman, T Masterman, AE Hensiek, SJ Sawcer, ... Neurology 64 (7), 1144-1151, 2005 | 1087 | 2005 |
| The TREAT‐NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations CL Bladen, D Salgado, S Monges, ME Foncuberta, K Kekou, K Kosma, ... Human mutation 36 (4), 395-402, 2015 | 746 | 2015 |
| Prevalence of muscular dystrophies: a systematic literature review A Theadom, M Rodrigues, R Roxburgh, S Balalla, C Higgins, ... Neuroepidemiology 43 (3-4), 259-268, 2015 | 345 | 2015 |
| HLA-DR 15 is associated with female sex and younger age at diagnosis in multiple sclerosis AE Hensiek, SJ Sawcer, R Feakes, J Deans, A Mander, E Akesson, ... Journal of Neurology, Neurosurgery & Psychiatry 72 (2), 184-187, 2002 | 206 | 2002 |
| Cerebellar ataxia, neuropathy, vestibular areflexia syndrome due to RFC1 repeat expansion A Cortese, S Tozza, WY Yau, S Rossi, SJ Beecroft, Z Jaunmuktane, ... Brain 143 (2), 480-490, 2020 | 195 | 2020 |
| Clinical outcomes in Duchenne muscular dystrophy: a study of 5345 patients from the TREAT-NMD DMD global database Z Koeks, CL Bladen, D Salgado, E Van Zwet, O Pogoryelova, ... Journal of neuromuscular diseases 4 (4), 293-306, 2017 | 169 | 2017 |
| Haplotypes and gene expression implicate the MAPT region for Parkinson disease: The GenePD Study JE Tobin, JC Latourelle, MF Lew, C Klein, O Suchowersky, HA Shill, ... Neurology 71 (1), 28-34, 2008 | 150 | 2008 |
| A whole genome screen for linkage disequilibrium in multiple sclerosis confirms disease associations with regions previously linked to susceptibility S Sawcer, M Maranian, E Setakis, V Curwen, E Akesson, A Hensiek, ... Brain 125 (6), 1337-1347, 2002 | 147 | 2002 |
| A retrospective study of the impact of lifestyle on age at onset of Huntington disease MK Trembath, ZA Horton, L Tippett, V Hogg, VR Collins, A Churchyard, ... Movement Disorders 25 (10), 1444-1450, 2010 | 125 | 2010 |
| The Gly2019Ser mutation in LRRK2is not fully penetrant in familial Parkinson's disease: the GenePD study JC Latourelle, M Sun, MF Lew, O Suchowersky, C Klein, LI Golbe, ... BMC medicine 6, 1-7, 2008 | 122 | 2008 |
| Striatal parvalbuminergic neurons are lost in Huntington's disease: implications for dystonia A Reiner, E Shelby, H Wang, Z DeMarch, Y Deng, NH Guley, V Hogg, ... Movement Disorders 28 (12), 1691-1699, 2013 | 115 | 2013 |
| The TREAT‐NMD D uchenne Muscular Dystrophy Registries: Conception, Design, and Utilization by Industry and Academia CL Bladen, K Rafferty, V Straub, S Monges, A Moresco, H Dawkins, A Roy, ... Human mutation 34 (11), 1449-1457, 2013 | 111 | 2013 |
| Mapping the differences in care for 5,000 spinal muscular atrophy patients, a survey of 24 national registries in North America, Australasia and Europe CL Bladen, R Thompson, JM Jackson, C Garland, C Wegel, A Ambrosini, ... Journal of neurology 261, 152-163, 2014 | 109 | 2014 |
| A genome screen for multiple sclerosis in Italian families S Broadley, S Sawcer, S D’Alfonso, A Hensiek, F Coraddu, J Gray, ... Genes & Immunity 2 (4), 205-210, 2001 | 94 | 2001 |
| Autonomic dysfunction is a major feature of cerebellar ataxia, neuropathy, vestibular areflexia ‘CANVAS’syndrome TY Wu, JM Taylor, DH Kilfoyle, AD Smith, BJ McGuinness, MP Simpson, ... Brain 137 (10), 2649-2656, 2014 | 89 | 2014 |
| Optical coherence tomography findings in Huntington’s disease: a potential biomarker of disease progression HM Kersten, HV Danesh-Meyer, DH Kilfoyle, RH Roxburgh Journal of neurology 262, 2457-2465, 2015 | 86 | 2015 |
| Widespread heterogeneous neuronal loss across the cerebral cortex in Huntington's disease AL Nana, EH Kim, DCV Thu, DE Oorschot, LJ Tippett, VM Hogg, BJ Synek, ... Journal of Huntington's disease 3 (1), 45-64, 2014 | 83 | 2014 |
| Cortical interneuron loss and symptom heterogeneity in Huntington disease EH Kim, DCV Thu, LJ Tippett, DE Oorschot, VM Hogg, R Roxburgh, ... Annals of neurology 75 (5), 717-727, 2014 | 82 | 2014 |
| Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double … B Schoser, M Roberts, BJ Byrne, S Sitaraman, H Jiang, P Laforêt, ... The Lancet Neurology 20 (12), 1027-1037, 2021 | 79 | 2021 |
| A novel RFC1 repeat motif (ACAGG) in two Asia-Pacific CANVAS families CK Scriba, SJ Beecroft, JS Clayton, A Cortese, R Sullivan, WY Yau, ... Brain 143 (10), 2904-2910, 2020 | 76 | 2020 |
